Solid pseudopapillary neoplasm (SPN) of the pancreas is a rare low-grade malignant neoplasm that accounts for 0.9%--2.7% of all exocrine pancreatic neoplasms. SPN was first reported by Frantz in 1959 \[[@b1-jptm-2016-06-16],[@b2-jptm-2016-06-16]\] and has previously been called a Frantz tumor, solid-pseudopapillary tumor, solid-cystic tumor, solid and papillary epithelial neoplasm, and papillary-cystic tumor. These tumors predominantly occur in young women, with a female-to-male ratio of 9:1 \[[@b1-jptm-2016-06-16]\]. SPN metastasizes in only 5%--15% of all cases, and common sites include the liver; portal, splenic, or superior mesenteric vein; spleen; omentum; peritoneum; duodenum; or other organs \[[@b1-jptm-2016-06-16],[@b2-jptm-2016-06-16]\]. The lung is a very rare metastatic site and has only been reported in three other cases in the literature \[[@b3-jptm-2016-06-16]-[@b5-jptm-2016-06-16]\]. In this study, we introduce a case of SPN with lung metastasis following 24 years of multiple recurrences.

CASE REPORT
===========

Clinical summary
----------------

A 61-year-old woman visited Korea University Guro Hospital (KUGH) for bilateral multiple lung nodules and a mass in the intrathoracic soft tissue. Twenty-four years prior, she had presented to KUGH with epigastric pain; computed tomography (CT) found a 9.9×8.6 cm heterogeneous mass in the pancreatic head. The tumor was removed and histologically diagnosed as SPN. After tumor removal, the patient underwent two choledochojejunostomy procedures but showed no sign of tumor recurrence. Nine years passed before her next visit for this same condition, when some newly developed nodules in her liver and peritoneum were biopsied and confirmed as metastatic SPN. During the next 15 years, the patient suffered eight additional metastatic recurrences in her liver, peritoneum, omentum, spleen, ovary, uterus, colon, mesocolon, and retroperitoneum before finally developing the present multiple lung metastases. A metastatectomy was performed to remove the lung nodules, and the patient is currently alive ([Fig. 1](#f1-jptm-2016-06-16){ref-type="fig"}). This study was approved by the Institutional Review Board (KUGH 15363-001) of KUGH.

Pathologic findings
-------------------

The clinical and pathologic features of the primary tumor were reviewed in the patient's electronic medical record. The glass slides and paraffin blocks that had been made from the recurrent tumors were also available for review. Overall, the tumors showed a pseudopapillary pattern with relatively monomorphic nuclei and abundant eosinophilic cytoplasm. However, we noted a certain degree of change over time, as summarized in [Table 1](#t1-jptm-2016-06-16){ref-type="table"}. In accordance with the histological changes, we subdivided the lesions into early (first to third operations), intermediate (fourth to seventh), and late (eighth to 11th) lesions. In the early metastatic lesions, the tumor showed frequent cystic changes with bland nuclei and indistinct necrobiotic nests without capsular invasion. The Ki-67 labeling index was also very low (\<1%). In the intermediate lesions, however, frequent necrobiotic nests (from the fourth to seventh) and capsular invasions (from the fifth) were noted. The Ki-67 labeling index, which was assessed using an image analysis program, increased to 5% (sixth). In the late lesions, malignant histological features, such as distinct tumor necrosis beyond necrobiotic nests (from the seventh), peritumoral infiltration of the soft tissue or organ (from the seventh), prominent solid architecture (from the eighth), nuclear atypia (from the ninth), and lymphatic emboli (11th), were seen ([Fig. 2A](#f2-jptm-2016-06-16){ref-type="fig"}--[D](#f2-jptm-2016-06-16){ref-type="fig"}). The average Ki-67 labeling index increased gradually (0.03%, 2.7%, and 5.6% in early, intermediate, and late metastatic lesions, respectively). Mitosis was usually absent with exceptions of 5/10 high-power field (HPF) (fifth) and 2/10 HPF (seventh) but did not show a significant change. All of the tumors showed identical immunohistochemical results and were diffusely positive for β-catenin, vimentin, neuron-specific enolase, CD10, cyclin D1, progesterone receptor, CD56, and synaptophysin. Interestingly, they were also positive for chromogranin A, which is very rare in SPN.

DISCUSSION
==========

Generally, the prognosis of SPN is good. Over 95% of patients with a solitary pancreatic lesion are cured by complete excision. Even with local spread, recurrences, or metastases, long periods of disease-free survival have been recorded \[[@b1-jptm-2016-06-16]\]. The general prevalence of metastatic SPN is 5%--15% \[[@b1-jptm-2016-06-16],[@b2-jptm-2016-06-16]\]. Debulking is recommended for these lesions in order to increase the chances of survival \[[@b6-jptm-2016-06-16]\]. The lung is a very rare metastatic site and was found in only three cases in the literature \[[@b3-jptm-2016-06-16]-[@b5-jptm-2016-06-16]\]. The first was reported in 2005 by Takahashi *et al*. \[[@b5-jptm-2016-06-16]\] and showed a lung lesion following three liver metastases. Hosokawa *et al*. \[[@b3-jptm-2016-06-16]\] reported the second case in 2014, which demonstrated concurrent portal vein and superior mesenteric arterial invasion. The third case was described by Xu *et al*. in 2015 \[[@b4-jptm-2016-06-16]\], with both liver and bone involvement. Two of the three cases showed a good survival outcome ([Table 2](#t2-jptm-2016-06-16){ref-type="table"}). Our case also reveals a long overall survival period despite many recurrences.

After reviewing the eight large studies in the literature, the most commonly quoted malignant SPN characteristics were nuclear atypia (5/8), angioinvasion (5/8), lymph node metastasis (4/8), mitotic count (3/8), advanced age (2/8), size (2/8), capsular invasion (2/8), perineural invasion (2/8), extra-pancreatic invasion (2/8), significant MIB-1 index (2/8), and prominent necrobiotic nests (1/8) \[[@b1-jptm-2016-06-16],[@b3-jptm-2016-06-16],[@b5-jptm-2016-06-16]-[@b10-jptm-2016-06-16]\]. Of the four cases with lung metastases (including ours), three showed liver metastasis, three exhibited capsular invasion, and two demonstrated necrobiotic nests ([Table 2](#t2-jptm-2016-06-16){ref-type="table"}). Our case initially presented with a bland-looking tumor; however, most of the malignant features including nuclear atypia, lymph node metastasis (upon CT), lymphatic invasion, large tumor size, capsular invasion, and necrobiotic nests developed in later metastases.

Though many studies have claimed that nuclear atypia is a malignant prognostic factor, there is still some debate on this topic. For example, Kim *et al*. \[[@b11-jptm-2016-06-16]\] recently suggested that some subsets of SPN with nuclear pleomorphism exist with stronger p53 immunoreactivity but do not appear to be more aggressive than conventional SPN. The 2010 World Health Organization classification for tumors of the pancreas also claims that nuclear atypia of pancreas SPN cannot predict malignant tumor behavior \[[@b12-jptm-2016-06-16]\]. In this study, nuclear atypia accompanied other malignant features. However, due to the patient's relatively good prognosis, the atypia is still a predictor of metastasis but should not be considered a poor prognostic indicator of overall survival. More studies of SPN focusing on nuclear atypia will be needed to further explain this connection.

In conclusion, this case depicts the aggressive progression of tumor cells by repeated peritoneal seeding and lymphatic invasion that still showed an indolent clinical course despite multiple recurrences, including the lung.

**Conflicts of Interest**

No potential conflict of interest relevant to this article was reported.

![Gross specimen of the patient's lung metastasis. A solid, well-demarcated and cystic mass with hemorrhage is seen.](jptm-2016-06-16f1){#f1-jptm-2016-06-16}

![Microscopic findings. (A) A loosely cohesive pseudopapillary pattern. (B) Capsular invasion with a cord or glandular pattern is visible in the intermediate and late metastatic lesions. (C) Necrobiotic nests are present in the intermediate lesions. (D) Distinct nuclear atypia is seen in the late lesions.](jptm-2016-06-16f2){#f2-jptm-2016-06-16}

###### 

Clinicopathological data of the patient

  Operation No.   Recurrence interval (mo)   Site                                                                     Size (largest diameter) (cm)   Necrobiotic nests   Necrosis   Capsular invasion   Ki-67 labeling index (%)   Solid architecture   Nuclear atypia   Mitotic count (/10HPF)
  --------------- -------------------------- ------------------------------------------------------------------------ ------------------------------ ------------------- ---------- ------------------- -------------------------- -------------------- ---------------- ------------------------
  1               0                          Pancreas                                                                 8                              NE                  NE         NE                  NE                         NE                   NE               NE
  2               107                        Liver, peritoneum                                                        5.5 (liver)                    N                   N          N                   \< 0.1                     N                    N                \< 1
  3               131                        Omentum, peritoneum                                                      4.3 (peritoneum)               N                   N          N                   \< 0.1                     N                    N                \< 1
  4               135                        Peritoneum                                                               1.3                            Y                   N          N                   \< 0.1                     N                    N                \< 1
  5               180                        Peritoneum                                                               3.5                            N                   N          Y                   0.2                        N                    N                5
  6               197                        Peritoneum                                                               5                              N                   N          Y                   5                          N                    N                \< 1
  7               205                        Liver, spleen, peritoneum, ovary                                         10 (ovary)                     Y                   Y          N                   2.9                        N                    N                2
  8               214                        Uterus, peritoneum, retroperitoneum, omentum, mesocolon, intrathoracic   3.8 (intrathoracic)            N                   Y          N                   12.4                       Y                    N                \< 1
  9               240                        Peritoneum, mesocolon, colon                                             1.5 (colon)                    N                   Y          Y                   6.6                        Y                    Y                \< 1
  10              272                        Spleen, retroperitoneum                                                  3.5 (retroperitoneum)          N                   Y          Y                   \< 0.1                     Y                    Y                \< 1
  11              284                        Lung, internal mammary soft tissue                                       2.8 (lung)                     N                   N          N                   3.4                        Y                    Y                \< 1

HPF, high power field; NE, not evaluable; N, absent; Y, present.

###### 

Cases of solid pseudopapillary neoplasm with lung metastasis

  Reference                                             Sex   Age (yr)   Primary site   Size (cm)   Malignant histologic features                                                  Metastasis          Operation                                  RI (mo)   Recurrence site                                                                                        Follow-up (mo)   Survival   Mitoses (/10HPF)   Ki-67 (%)
  ----------------------------------------------------- ----- ---------- -------------- ----------- ------------------------------------------------------------------------------ ------------------- ------------------------------------------ --------- ------------------------------------------------------------------------------------------------------ ---------------- ---------- ------------------ -----------
  Takahashi *et al*. (2005) \[[@b5-jptm-2016-06-16]\]   F     41         Tail           12          Capsule invasion, necrobiotic nests, venous invasion                           Liver (multiple)    Distal pancreatectomy, metastatectomy      14        Liver, multiple (14 mo); liver, multiple (27 mo); liver, multiple (38 mo); lung, single (41 mo)        60               Alive      5                  10
  Hosokawa *et al*. (2014) \[[@b3-jptm-2016-06-16]\]    F     24         Head           6           Capsule invasion, per pancreatic tissue                                        PV, SMA, lung       PPPD, PV, resection, pulmonary resection   None      None                                                                                                   34               Alive      \-                 1.5
  Xu *et al*. (2015) \[[@b4-jptm-2016-06-16]\]          F     42         Body           13          NE                                                                             Liver, lung, bone   NE                                         NE        NE                                                                                                     NE               NE         NE                 NE
  Our case (2016)                                       F     37         Head           8.6         Capsule invasion, necrobiotic nests, lymphatic invasion, lymph node invasion   None                PPPD                                       107       Liver, spleen, abdominal mesentery, mesocolon, retroperitoneum, ovary, uterus, lung, thoracic cavity   284              Alive      2                  5

RI, recurrence interval; HPF, high power field; F, female; PV, portal vein; SMA, superior mesenteric artery; PPPD, pylorus-preserving pancreaticoduodenectomy; NE, not evaluable.
